HighGravityDataCurrent guidance
26 items
Cencora
Guidance from Cencora’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Aug 5, 2026
Data checked
Aug 5, 2026
What changed in the Aug 5, 2026 release
Each item compared with the same item in the previous release (May 6, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Lowered | International Healthcare Solutions Segment Revenue | for FY2026 | “8% to 10% growth” | “~8% growth” | Filing ↗ |
| Raised | Other Revenue | for FY2026 | “1% to 5% growth” | “~6% growth” | Filing ↗ |
| Raised | Adjusted diluted earnings per share | for FY2026 | “$17.65 to $17.90” | “$17.75 to $17.95” | Filing ↗ |
| Raised | Adjusted Diluted EPS | for FY2026 | “$17.65 to $17.90” | “$17.75 to $17.95” | Filing ↗ |
| Narrowed | Adjusted operating income | for FY2026 | “12% to 14% growth” | “13% to 14% growth” | Filing ↗ |
| Raised | International Healthcare Solutions Segment (2)(3) - Adjusted operating income | for FY2026 | “5% to 8% growth” | “~9% growth” | Filing ↗ |
| New | Other (2) - Adjusted operating income | for FY2026 | — | “~10% growth” | Filing ↗ |
| Narrowed | U.S. Healthcare Solutions Segment (2) - Adjusted operating income | for FY2026 | “14% to 16% growth” | “14.5% to 15.5% growth” | Filing ↗ |
| Lowered | Diluted weighted average shares outstanding | for FY2026 | “Under 195.5M” | “~194M” | Filing ↗ |
| Raised | Net interest expense | for FY2026 | “~$485M” | “~$490M” | Filing ↗ |
| Raised | Other (2) | for FY2026 | “1% to 5% growth” | “~6% growth” | Filing ↗ |
| Reiterated | Revenue | for FY2026 | “4% to 6% growth” | “4% to 6% growth” | Filing ↗ |
| Reiterated | U.S. Healthcare Solutions Segment Revenue | for FY2026 | “4% to 6% growth” | “4% to 6% growth” | Filing ↗ |
| Reiterated | Adjusted effective tax rate | for FY2026 | “~20%” | “~20%” | Filing ↗ |
| Reiterated | Adjusted free cash flow | for FY2026 | “~$3.0B” | “~$3.0B” | Filing ↗ |
| Reiterated | Capital expenditures | for FY2026 | “~$900M” | “~$900M” | Filing ↗ |
Show 6 items not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Planned investments to strengthen U.S. distribution network | for FY2030 | “$1 billion” | — | Filing ↗ |
| Not restated | Revenue - International Healthcare Solutions Segment | for FY2026 | “7% to 9% growth” | — | Filing ↗ |
| Not restated | Other (1) - Adjusted operating income | for FY2026 | “1% to 4% decline” | — | Filing ↗ |
| Not restated | Adjusted operating income | for the long term | “6% to 9%” | — | Filing ↗ |
| Not restated | Other (1) | for FY2026 | “0% to 4% growth” | — | Filing ↗ |
| Not restated | Capital deployment | for the long term | “3% to 4%” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| International Healthcare Solutions Segment Revenue | “~8% growth” | for FY2026 | GAAP-tied | Nov 5, 2025 | 3 | Filing ↗ |
| Other Revenue | “~6% growth” | for FY2026 | GAAP-tied | Nov 5, 2025 | 3 | Filing ↗ |
| Revenue | “4% to 6% growth” | for FY2026 | GAAP-tied | Nov 5, 2025 | 4 | Filing ↗ |
| Revenue - International Healthcare Solutions Segment | “7% to 9% growth” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| Revenue - Other | “1% to 5% growth” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| U.S. Healthcare Solutions Segment Revenue | “4% to 6% growth” | for FY2026 | GAAP-tied | Nov 5, 2025 | 3 | Filing ↗ |
| Adjusted diluted earnings per share | “$17.75 to $17.95” | for FY2026 | Company-defined | Nov 5, 2025 | 4 | Filing ↗ |
| Adjusted Diluted EPS | “$17.75 to $17.95” | for FY2026 | Company-defined | Feb 2, 2026 | 3 | Filing ↗ |
| Adjusted operating income | “13% to 14% growth” | for FY2026 | Company-defined | Nov 5, 2025 | 4 | Filing ↗ |
| International Healthcare Solutions Segment (1)(2) - Adjusted operating income | “5% to 8% growth” | for FY2026 | Company-defined | Nov 5, 2025 | 1 | Filing ↗ |
| International Healthcare Solutions Segment (2)(3) - Adjusted operating income | “~9% growth” | for FY2026 | Company-defined | Feb 2, 2026 | 3 | Filing ↗ |
| Other (1) - Adjusted operating income | “1% to 4% decline” | for FY2026 | Company-defined | Nov 5, 2025 | 1 | Filing ↗ |
| Other (2) - Adjusted operating income | “~10% growth” | for FY2026 | Company-defined | Aug 5, 2026 | 1 | Filing ↗ |
| U.S. Healthcare Solutions Segment (1) - Adjusted operating income | “9% to 11% growth” | for FY2026 | Company-defined | Nov 5, 2025 | 1 | Filing ↗ |
| U.S. Healthcare Solutions Segment (2) - Adjusted operating income | “14.5% to 15.5% growth” | for FY2026 | Company-defined | Feb 2, 2026 | 3 | Filing ↗ |
| Adjusted effective tax rate | “~20%” | for FY2026 | Company-defined | Nov 5, 2025 | 4 | Filing ↗ |
| Adjusted free cash flow | “~$3.0B” | for FY2026 | Company-defined | Nov 5, 2025 | 4 | Filing ↗ |
| Capital expenditures | “~$900M” | for FY2026 | Company-defined | Nov 5, 2025 | 4 | Filing ↗ |
| Diluted weighted average shares outstanding | “~194M” | for FY2026 | GAAP-tied | Nov 5, 2025 | 4 | Filing ↗ |
| Net interest expense | “~$490M” | for FY2026 | Company-defined | Nov 5, 2025 | 4 | Filing ↗ |
| Other (1) | “0% to 4% growth” | for FY2026 | Company-defined | Nov 5, 2025 | 1 | Filing ↗ |
| Other (2) | “~6% growth” | for FY2026 | Company-defined | Feb 2, 2026 | 3 | Filing ↗ |
| Quarterly cash dividend | “$0.60 per common share” | for FY2026 | Declared action | Feb 2, 2026 | 3 | Filing ↗ |
| Repurchase in Shares | “$1 Billion” | for FY2026 | Declared action | May 6, 2026 | 1 | Filing ↗ |
Next year and medium term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Planned investments to strengthen U.S. distribution network | “$1 billion” | for FY2030 | Company-defined | Nov 5, 2025 | 1 | Filing ↗ |
Long term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Adjusted diluted earnings per share | “9% to 13%” | for the long term | Company-defined | Nov 5, 2025 | 1 | Filing ↗ |
| Adjusted operating income | “6% to 9%” | for the long term | Company-defined | Nov 5, 2025 | 1 | Filing ↗ |
| Capital deployment | “3% to 4%” | for the long term | Company-defined | Nov 5, 2025 | 1 | Filing ↗ |
No period stated
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Quarterly dividend | “$0.60 per common share” | — | Declared action | Nov 6, 2024 | 2 | Filing ↗ |
How one item moved
Adjusted operating income, for FY2026 — every statement across the year, each linked to its filing.
How your Healthcare payers & distributors sector group guides
12 companies in Healthcare payers & distributors. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| UnitedHealth Group | Oct 13, 2026 | 5 changes |
| Cardinal Health | Aug 11, 2026 | 13 changes |
| Cencora | Aug 5, 2026 | 11 changes |
| CVS Health | Aug 5, 2026 | 5 changes |
| McKesson | Aug 5, 2026 | 1 change |
| Labcorp | Jul 30, 2026 | 2 changes |
| The Cigna Group | Jul 30, 2026 | 3 changes |
| Humana | Jul 29, 2026 | 4 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2030 | FY2026 | FY2025 | Long-term | No period |
|---|---|---|---|---|---|
| International Healthcare Solutions revenue growth | — | — | 1 statement | — | — |
| International Healthcare Solutions Segment Revenue | — | 4 statements | 3 statements | — | — |
| International Healthcare Solutions segment revenue growth (constant currency basis) | — | — | 2 statements | — | — |
| Other Revenue | — | 4 statements | — | — | — |
| Revenue | — | 4 statements | 2 statements | — | — |
The full record for Cencora and its Healthcare payers & distributors peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Aug 5, 2026 | FY2026 Q3 | 0001140859-26-000032 | 17 | Open filing ↗ |
| May 6, 2026 | FY2026 Q2 | 0001140859-26-000018 | 17 | Open filing ↗ |
| Feb 2, 2026 | FY2026 Q1 | 0001140859-26-000004 | 15 | Open filing ↗ |
| Nov 5, 2025 | FY2025 Q4 | 0001140859-25-000128 | 20 | Open filing ↗ |
| Aug 6, 2025 | FY2025 Q3 | 0001140859-25-000119 | 10 | Open filing ↗ |
| May 7, 2025 | FY2025 Q2 | 0001140859-25-000081 | 9 | Open filing ↗ |
| Feb 5, 2025 | FY2025 Q1 | 0001140859-25-000032 | 10 | Open filing ↗ |
| Nov 6, 2024 | FY2024 Q4 | 0001140859-24-000148 | 10 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error